Please login to the form below

Not currently logged in
Email:
Password:

MRSA

This page shows the latest MRSA news and features for those working in and with pharma, biotech and healthcare.

Basilea moves closer to US filing of novel antibiotic

Basilea moves closer to US filing of novel antibiotic

MRSA). Results from that trial are due in 2021 and if positive will clear the way for an FDA filing. ... the high incidence of MRSA in US hospitals and the higher propensity in the US to use novel products”.

Latest news

  • Motif Bio preps US filing after antibiotic clears phase III Motif Bio preps US filing after antibiotic clears phase III

    resistance to other antibiotics, including ‘superbugs’ such as methicillin resistant Staphylococcus aureus (MRSA).

  • CHMP backs AZ's 'superbug' antibiotic product CHMP backs AZ's 'superbug' antibiotic product

    In 2011 AZ launched novel cephalosporin Zinforo (ceftaroline fosamil), the first drug in the class to be approved with data showing it could tackle the superbug methicillin-resistant Staphylococcus aureus (MRSA).

  • Pfizer takes MRSA vaccine into phase IIb trial Pfizer takes MRSA vaccine into phase IIb trial

    Trial will involve patients undergoing elective spinal fusion surgery.  . Pfizer has started enrolling patients into a mid-stage trial of its candidate vaccine for 'superbug' methicillin-resistant Staphylococcus aureus (MRSA). ... The company is trying

  • Basilea’s novel antibiotic reaches UK market Basilea’s novel antibiotic reaches UK market

    It is a broad-spectrum antibiotic and can be used to treat infections caused both Gram- positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas species. ... Treatment failure rates in pneumonia,

  • Cubist gets green light from FDA for new antibiotic Sivextro Cubist gets green light from FDA for new antibiotic Sivextro

    Sivextro is in the oxazolidinone class of antibiotics has been approved to treat ABSSSIs caused by certain Gram-positive bacteria, including 'superbug' methicillin-resistant Staphylococcus aureus (MRSA), and is available in ... Until the approval of

More from news
Approximately 4 fully matching, plus 77 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....